Cargando…
Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
BACKGROUND/OBJECTIVE: Pemigatinib, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, is a novel therapeutic approach for treating cholangiocarcinoma when an FGFR fusion or gene rearrangement is identified. Although the most reported side effect of pemigatinib is hyperphosphatemia, tumoral ca...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Association of Clinical Endocrinology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508588/ https://www.ncbi.nlm.nih.gov/pubmed/36189136 http://dx.doi.org/10.1016/j.aace.2022.07.001 |